Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

Silexion Therapeutics Corp. announced that it will present a poster at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco, scheduled for January 23-25, 2025. The presentation will focus ...

Silexion Therapeutics Corp. announced promising results from preclinical studies of its RNA interference therapy, SIL204, for KRAS-driven pancreatic cancer. The research, conducted in orthotopic ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

Techniques such as RNA interference (RNAi), RNA editing, and the CRISPR/Cas system are being explored to target specific RBPs and circRNAs. By disrupting harmful circRNA-RBP interactions or enhancing ...

Novartis has agreed to license and develop Arrowhead Pharmaceuticals’ preclinical stage small interfering RNA (siRNA) therapy ARO-SNCA, a potential treatment for Parkinson’s disease and other ...

The vector consists of a polyethylene glycolylated liposomal outer coat (providing immune evasion and prolonged circulation), a spindle-shaped nanomotor (resembling a flagellum, facilitating targeted ...

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...